A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Authors: Dai Maruyama, Erica J. Gomez, Muhammad Jalaluddin, Kamel Izeradjene, Edward Greenberg, Cyril Ramathal, Matthew Ku